| 1 |
34510814 | Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy. | 2022 Feb |
1 |
| 2 |
34914863 | The impact of androgen deprivation therapy on bone mineral density in men treated for paraphilic disorder: A retrospective cohort study. | 2022 Mar |
1 |
| 3 |
34923058 | An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. | 2022 Jun 1 |
5 |
| 4 |
35108137 | Advances with androgen deprivation therapy for prostate cancer. | 2022 Feb 2 |
4 |
| 5 |
32655041 | Androgen deprivation therapy and side effects: are GnRH antagonists safer? | 2021 Jan-Feb |
1 |
| 6 |
34194398 | Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies. | 2021 |
2 |
| 7 |
34216282 | Cardiovascular Toxicity of Androgen Deprivation Therapy. | 2021 Jul 3 |
2 |
| 8 |
34408793 | Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. | 2021 |
3 |
| 9 |
34881062 | Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists. | 2021 |
3 |
| 10 |
32208461 | Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer. | 2020 |
2 |
| 11 |
32333736 | The role of FSH and LH in prostate cancer and cardiometabolic comorbidities. | 2020 Apr |
1 |
| 12 |
32773255 | Indications and Complications of Androgen Deprivation Therapy. | 2020 Aug |
1 |
| 13 |
32900627 | Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer. | 2020 Dec |
1 |
| 14 |
30497883 | Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. | 2019 Apr |
2 |
| 15 |
30637900 | Androgen deprivation therapy for prostate cancer and risk of dementia. | 2019 Jul |
1 |
| 16 |
31127324 | [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer]. | 2019 Oct |
1 |
| 17 |
31247696 | [Gonadotroph Pituitary Adenoma Causing Severe Headache Following Repeated Use of GnRH Agonist for Prostate Cancer]. | 2019 May |
2 |
| 18 |
30574196 | Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy. | 2018 Dec |
1 |
| 19 |
27232853 | No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study. | 2017 Jul-Aug |
2 |
| 20 |
28417429 | Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease. | 2017 Jun |
4 |
| 21 |
26004800 | Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. | 2016 Jan |
1 |
| 22 |
26637324 | [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?]. | 2016 Feb |
3 |
| 23 |
26768279 | Study of testosterone-guided androgen deprivation therapy in management of prostate cancer. | 2016 Feb |
1 |
| 24 |
27083586 | [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists]. | 2016 Dec |
6 |
| 25 |
27246172 | An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. | 2016 Jul |
2 |
| 26 |
25512159 | Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. | 2015 Jun |
1 |
| 27 |
25592210 | ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. | 2015 Jan |
1 |
| 28 |
25732167 | Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. | 2015 Apr 10 |
1 |
| 29 |
25990353 | Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. | 2015 Sep |
2 |
| 30 |
23428068 | Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer. | 2014 Mar |
2 |
| 31 |
23883294 | Preferred treatment frequency in patients receiving androgen deprivation therapy for advanced prostate cancer. | 2014 Apr |
1 |
| 32 |
24378335 | Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. | 2014 Apr |
1 |
| 33 |
24495466 | Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. | 2014 Dec |
1 |
| 34 |
25251952 | External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer. | 2014 Jul-Aug |
1 |
| 35 |
22751146 | New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. | 2013 Mar |
2 |
| 36 |
23292083 | Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies. | 2013 Feb |
1 |
| 37 |
23601449 | Prevalence of patients with nonmetastatic prostate cancer on androgen deprivation therapy in the United States. | 2013 Jun |
1 |
| 38 |
23984804 | Agonists of luteinizing hormone-releasing hormone in prostate cancer. | 2013 Nov |
1 |
| 39 |
22114014 | Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States. | 2012 Jan |
1 |
| 40 |
22294742 | Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer. | 2012 Mar |
1 |
| 41 |
22511442 | Stimulation of a non-functioning pituitary macroadenoma after administration of goserelin acetate for locally advanced prostate cancer causing a sustained elevation in PSA and testosterone. | 2012 Apr |
2 |
| 42 |
23046037 | Landmarks in hormonal therapy for prostate cancer. | 2012 Oct |
2 |
| 43 |
23163498 | Systemic bias in the medical literature on androgen deprivation therapy and its implication to clinical practice. | 2012 Dec |
1 |
| 44 |
23172994 | LHRH Agonists for the Treatment of Prostate Cancer: 2012. | 2012 |
2 |
| 45 |
23177744 | Vocal changes in patients with prostate cancer following androgen ablation. | 2012 Nov |
1 |
| 46 |
21109456 | Androgen deprivation therapy and cataract incidence among elderly prostate cancer patients in the United States. | 2011 Mar |
1 |
| 47 |
21904569 | An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. | 2011 Jun |
3 |
| 48 |
22009028 | Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. | 2011 Nov 22 |
2 |
| 49 |
20404727 | Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. | 2010 Jun |
1 |
| 50 |
20628233 | Titration of dosage for the protective effect of zoledronic acid on bone loss in patients submitted to androgen deprivation therapy due to prostate cancer: a prospective open-label study. | 2010 |
1 |